Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

37.23 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

4 High-Risk Stocks Built for Big Returns ↗

October 14, 2026

These speculative investments could turbocharge a portfolio to market-beating returns.

Via The Motley Fool

Topics Artificial Intelligence

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

August 11, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

Agios Pharmaceuticals (NASDAQ:AGIO) Surges on Q2 Revenue Beat Driven by PYRUKYND Sales ↗

July 30, 2026

Via Chartmill

Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Beat Drives Stock Rally ↗

April 29, 2026

Via Chartmill

Topics Earnings

Agios Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company...

Via MarketBeat

Topics Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗

July 10, 2026

An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.

Via The Motley Fool

Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) ↗

July 07, 2026

The company received some good news on its most important drug today.

Via The Motley Fool

The market is filled with gapping stocks in Tuesday's session. ↗

July 07, 2026

Via Chartmill

Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss ↗

June 13, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) used an investor webcast tied to the 2026 European Hematology Association Congress in Stockholm to highlight new clinical data for mitapivat across thalassemia and...

Via MarketBeat

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

May 22, 2026

From Avanzanite Bioscience B.V. and Agios Pharmaceuticals, Inc.

Via Business Wire

Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances ↗

May 19, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently...

Via MarketBeat

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) ↗

May 02, 2026

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.

Via The Motley Fool

Agios (AGIO) Q1 2026 Earnings Call Transcript ↗

April 30, 2026

Agios (AGIO) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday ↗

April 29, 2026

There's power in the company's No. 1 molecule.

Via The Motley Fool

Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) ↗

April 24, 2026

A rival company's trial results had a negative impact on Agios' stock this week.

Via The Motley Fool

Agios (AGIO) Q3 2024 Earnings Call Transcript ↗

April 22, 2026

Agios (AGIO) Q3 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Agios (AGIO) Q2 2025 Earnings Call Transcript ↗

April 21, 2026

Agios (AGIO) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Agios (AGIO) Q3 2025 Earnings Transcript ↗

April 21, 2026

Agios (AGIO) Q3 2025 Earnings Transcript

Via The Motley Fool

Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗

April 20, 2026

Via Chartmill

Here's Why Agios Pharmaceuticals Crashed 23% Today ↗

April 20, 2026

The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.

Via The Motley Fool

What's going on in today's session ↗

April 20, 2026

Via Chartmill

These stocks are gapping in today's session ↗

April 20, 2026

Via Chartmill

Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? ↗

March 31, 2026

.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.

Via Benzinga

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today ↗

March 31, 2026

The young drugmaker's sickle cell treatment is receiving special consideration from the United States' top drug regulator.

Via The Motley Fool

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything ↗

March 31, 2026

Focused on therapies for rare blood disorders, this biotech saw a notable insider sale amid ongoing clinical development efforts.

Via The Motley Fool

Topics Regulatory Compliance

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Agios (AGIO) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Agios (AGIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.